银诺医药-B（02591）于2026年9月3日发布2026年8月股份变动月报表。公告显示，截至2026年8月31日，公司法定/注册股本为人民币456,819,349元，均为每股面值人民币1元的普通股。其中，已于香港联交所上市的H股为420,285,370股，非上市股份为36,533,979股。报告期内，公司上述注册股本及已发行股份数量均保持不变，无新增发行、购回、注销或以库藏形式持有的股份。
公告同时显示，公司在当月并未涉及股份期权或股权激励计划的授出、行使或失效，也无承诺发行公司股份的权证及可换股票据等其他股份交易安排。截至8月底，公司H股和非上市股份的已发行及登记情况保持稳定，公眾持股比例符合香港联交所《上市规则》的相关要求。
据悉，本次公告由联席公司秘书杨东妍签署，公司亦确认继续遵守香港联交所《上市规则》等相关法律法规。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.